Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

‘Encouraging’ Responses Seen With Durvalumab Plus R-CHOP in DLBCL

Key clinical point: Durvalumab plus R-CHOP produced complete responses in patients with previously untreated, high-risk diffuse large B-cell lymphoma (DLBCL).

Major finding: Durvalumab plus R-CHOP induction produced a complete response rate of 54%.

Study details: A phase 2 trial of 43 patients with previously untreated, high-risk DLBCL.

Disclosures: The trial was sponsored by Celgene. Researchers reported relationships with Celgene and other companies.

Citation:

Nowakowski GS et al. ASCO 2019, Abstract 7520.